Akari Therapeutics (AKTX) announced the appointment of Samir Patel as CEO. Patel has served as interim CEO since May 2024. Additionally, the company announced it has appointed Abizer Gaslightwala to its Board of Directors. Michael Grissinger, a member of the Board of Directors, provided notice of his resignation on December 16, 2024. Patel currently serves as founder and principal of PranaBio Investments, a firm providing consulting, strategic advisory, and investment services for small cap biotechnology companies. He is also a consultant to GE Global Research. Gaslightwala currently serves as the SVP and Franchise Head for Oncology at Jazz Pharmaceuticals (JAZZ).
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AKTX:
- Akari Therapeutics Appoints Torsten Hombeck as CFO
- Akari Therapeutics appoints Torsten Hombeck as CFO
- Akari Therapeutics Announces Leadership Restructuring
- Biotech Alert: Searches spiking for these stocks today
- Akari Therapeutics regains full Nasdaq comliance
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
